Clinical Trial Update: DESTINY-PANTUMOUR04

View source ↗

Summary

Clinical trial update for the DESTINY-PANTUMOUR04 study sponsored by AstraZeneca, evaluating trastuzumab deruxtecan across multiple cancer types with recruitmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Anal Cancer
• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Renal Cell Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan) (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Adenocarcinoma (NOS), Anal Cancer | Status: RECRUITING